CN115066255A - 合成的dna载体和使用方法 - Google Patents

合成的dna载体和使用方法 Download PDF

Info

Publication number
CN115066255A
CN115066255A CN202080080113.0A CN202080080113A CN115066255A CN 115066255 A CN115066255 A CN 115066255A CN 202080080113 A CN202080080113 A CN 202080080113A CN 115066255 A CN115066255 A CN 115066255A
Authority
CN
China
Prior art keywords
dna vector
dna
disorder
factor
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080080113.0A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁斯·C·施耐普
菲利普·R·约翰逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aldeflon LLC
Original Assignee
Star Therapy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Star Therapy Ltd filed Critical Star Therapy Ltd
Publication of CN115066255A publication Critical patent/CN115066255A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080080113.0A 2019-09-18 2020-09-18 合成的dna载体和使用方法 Pending CN115066255A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902084P 2019-09-18 2019-09-18
US62/902,084 2019-09-18
PCT/US2020/051507 WO2021055760A1 (en) 2019-09-18 2020-09-18 Synthetic dna vectors and methods of use

Publications (1)

Publication Number Publication Date
CN115066255A true CN115066255A (zh) 2022-09-16

Family

ID=74884687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080113.0A Pending CN115066255A (zh) 2019-09-18 2020-09-18 合成的dna载体和使用方法

Country Status (12)

Country Link
US (6) US11766490B2 (enExample)
EP (1) EP4031168A4 (enExample)
JP (2) JP2022549138A (enExample)
KR (1) KR20220128607A (enExample)
CN (1) CN115066255A (enExample)
AU (1) AU2020351204A1 (enExample)
CA (1) CA3151464A1 (enExample)
GB (2) GB2700048B (enExample)
IL (1) IL291437A (enExample)
MX (1) MX2022003291A (enExample)
TW (1) TW202124722A (enExample)
WO (1) WO2021055760A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020009579A (es) * 2018-03-15 2020-11-09 Intergalactic Therapeutics Inc Vectores de adn sintetico y metodos de uso.
CN109735558B (zh) * 2018-12-12 2022-04-15 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
WO2021055760A1 (en) * 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use
WO2022169774A1 (en) * 2021-02-02 2022-08-11 University Of Massachusetts Inverted terminal repeats from aav serotypes 8 and rh.39 in gene therapy vectors
JP2024535917A (ja) * 2021-09-27 2024-10-02 アルデブロン，エル．エル．シー． 環状ｄｎａベクターの合成による生成
AU2022367527A1 (en) * 2021-10-15 2024-05-02 Aldevron, Llc Respiratory delivery of therapeutic agents
EP4453181A4 (en) * 2021-12-20 2025-12-24 Aldevron Llc GENE THERAPY VECTOR PRODUCTION IN MODIFIED BACTERIA
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性ｄｎａベクター
KR20250034991A (ko) 2022-08-16 2025-03-11 알데브론 엘엘씨 합성 환형 핵산 생산을 위한 무세포 방법
WO2024115669A1 (en) * 2022-11-30 2024-06-06 Evaxion Biotech A/S Process for production of synthetic circular dna
WO2026064802A1 (en) * 2024-09-23 2026-03-26 The General Hospital Corporation Gene therapy platform to restore gabaergic inhibition and improve cognition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032092A1 (en) * 1995-02-23 2003-02-13 Francis Blanche DNA molecules, preparation and use in gene therapy
US20130203121A1 (en) * 2010-10-05 2013-08-08 Rentschler Biotechnologie Gmbh Methods for the semi-synthetic production of high purity "minicircle" dna vectors from plasmids
US20170327797A1 (en) * 2015-01-27 2017-11-16 Hoffmann-La Roche Inc. Recombinant hbv cccdna, the method to generate thereof and the use thereof
US20180305701A1 (en) * 2017-03-14 2018-10-25 Baylor College Of Medicine Targeting minivectors to specific tissue using shape
US20190169637A1 (en) * 2015-09-22 2019-06-06 Julius-Maximilians-Universität Würzburg A method for high level and stable gene transfer in lymphocytes
CN111954528A (zh) * 2018-03-15 2020-11-17 星际治疗有限公司 合成dna运载体及使用方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2488641A (en) * 1947-06-17 1949-11-22 Herschel V Seawright Revolving display rack for showcases
US6027722A (en) 1990-10-25 2000-02-22 Nature Technology Corporation Vectors for gene transfer
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
AU7353494A (en) * 1993-11-12 1995-05-29 Case Western Reserve University Episomal expression vector for human gene therapy
FR2731014B1 (fr) 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US7030098B2 (en) 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
CN1264854C (zh) 1999-05-28 2006-07-19 坎布雷科斯生物科学巴尔的摩公司 Dna纯化方法和纯化的dna
EP1224313A1 (en) * 1999-10-07 2002-07-24 University of Iowa Research Foundation Adeno-associated viruses and uses thereof
EP1317560A4 (en) 2000-09-08 2005-10-05 Gen Hospital Corp DNA VECTORS WHICH COULD REENGANIZE
US20070196838A1 (en) 2000-12-08 2007-08-23 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20030082559A1 (en) 2001-01-19 2003-05-01 David Beach Methods and reagents for amplification and manipulation of vector and target nucleic acid sequences
FR2821855B1 (fr) * 2001-03-09 2004-04-02 Cayla Genes synthetiques et plasmides bacteriens depourvus de cpg
EP2801614B1 (en) 2002-08-29 2019-05-15 The Board of Trustees of the Leland Stanford Junior University Circular nucleic acid vectors and methods for making and using the same
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
US20050069991A1 (en) * 2003-03-25 2005-03-31 Hyman Edward D. Method for plasmid preparation by conversion of open circular plasmid to supercoiled plasmid
AT412400B (de) 2003-05-08 2005-02-25 Mayrhofer Peter Mag Dr Minicircle-herstellung
US8802643B1 (en) 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
ATE340264T1 (de) * 2003-06-10 2006-10-15 Mologen Ag Zirkuläres expressionskonstrukt für gentherapeutische anwendungen
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
GB0315160D0 (en) * 2003-06-28 2003-08-06 Royal Holloway University Of L In vitro amplification of DNA
EP1781800B1 (en) 2004-08-19 2013-06-19 Nature Technology Corp. Process for plasmid dna fermentation
WO2006063355A2 (en) * 2004-12-11 2006-06-15 Cytogenix , Inc. Cell free biosynthesis of high-quality nucleic acid and uses thereof
US7796986B2 (en) * 2005-03-11 2010-09-14 Atc Technologies, Llc Modification of transmission values to compensate for interference in a satellite down-link communications
US7622252B2 (en) 2005-06-10 2009-11-24 Baylor College Of Medicine Generation of minicircle DNA with physiological supercoiling
WO2007018744A2 (en) * 2005-08-03 2007-02-15 Cytogenix, Inc. Cell-free biosynthesis of nucleic acid
US20080318283A1 (en) 2006-02-01 2008-12-25 Clague P. Hodgson Fermentation Process for Continuous Plasmid Dna Production
EP2160459A2 (en) 2007-05-23 2010-03-10 Nature Technology Corp. Improved e. coli plasmid dna production
AU2008262478B9 (en) 2007-05-29 2014-06-19 Aldevron, L.L.C. Vectors and methods for genetic immunization
AU2009231171A1 (en) 2008-04-02 2009-10-08 Fondazione Telethon Method of treating genetic disorders
US8945885B2 (en) 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
US8921072B2 (en) * 2008-09-02 2014-12-30 General Electric Compnay Methods to generate DNA mini-circles
US8486630B2 (en) * 2008-11-07 2013-07-16 Industrial Technology Research Institute Methods for accurate sequence data and modified base position determination
US9045759B2 (en) 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
US8460924B2 (en) 2009-10-16 2013-06-11 Baylor College Of Medicine Supercoiled minivectors™ for gene therapy applications
US9506082B2 (en) 2010-04-12 2016-11-29 Nature Technology Corporation Eukaryotic expression vectors resistant to transgene silencing
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
CN104245719B (zh) 2011-12-12 2016-09-14 宾夕法尼亚大学托管会 包含改进的il-12基因构建体的组合物和疫苗、免疫治疗剂及其使用方法
EP2812436A4 (en) 2012-02-10 2016-05-11 Univ Leland Stanford Junior MINI-INTRONIC PLASMID VECTORS
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
WO2013181440A1 (en) 2012-05-30 2013-12-05 Baylor College Of Medicine Supercoiled minivectors as a tool for dna repair, alteration and replacement
US20150322439A1 (en) 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
EP2931318A4 (en) 2012-12-13 2016-07-20 Univ Pennsylvania DNA ANTIBODY CONSTRUCTS AND METHODS FOR USE THEREOF
US9931392B2 (en) * 2013-01-18 2018-04-03 London School Of Hygiene And Tropical Medicine Glycosylation method
US9701981B2 (en) 2013-03-15 2017-07-11 The Board Of Trustees Of The Leland Stanford Junior University Nucleosome-excluding sequences (NES) as a DNA spacer in vectors results in prolonged transgene expression in eukaryotic cells
GB201307075D0 (en) 2013-04-19 2013-05-29 Mayrhofer Peter Plasmid for minicircle production
US10604771B2 (en) 2013-05-10 2020-03-31 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CN104342453A (zh) 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
WO2016094639A1 (en) 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
CA2975855C (en) 2015-02-04 2025-09-23 Twist Bioscience Corporation SYNTHETIC GENE COMPOSITIONS AND ASSEMBLY METHODS
GB201502137D0 (en) * 2015-02-09 2015-03-25 Ucl Business Plc Treatment
US10426847B2 (en) 2015-03-26 2019-10-01 Oncosec Medical Incorporated Method for the treatment of malignancies
AU2016260401B2 (en) 2015-05-14 2022-05-19 St. Jude Children's Research Hospital, Inc. Nucleic acid molecules containing spacers and methods of use thereof
AU2016355343C1 (en) 2015-11-19 2024-10-03 Lloyd G. Mitchell Compositions and methods for correction of heritable ocular disease
SG10201913163PA (en) 2015-12-18 2020-03-30 Oncosec Medical Inc Plasmid constructs for heterologous protein expression and methods of use
EP3205356A1 (en) 2016-02-10 2017-08-16 Onkoloski Institut Ljubljana Plasmid expression vector encoding human interleukin 12 under transcriptional control of p21 promoter and without antibiotic resistance for cancer gene therapy and other uses thereof
IL261524B2 (en) 2016-03-03 2023-10-01 Univ Massachusetts End-capped linear double-stranded DNA for non-viral gene transfer
US10077459B2 (en) 2016-05-04 2018-09-18 General Electric Company Cell-free protein expression using rolling circle amplification product
WO2018111914A1 (en) 2016-12-14 2018-06-21 Synthetic Genomics, Inc. Methods for assembling dna molecules
CN110446783A (zh) 2017-02-28 2019-11-12 奥利希罗基因组学有限公司 环状dna的复制或扩增方法
CA3056211A1 (en) 2017-03-21 2018-09-27 Stylianos MICHALAKIS Gene therapy for the treatment of cngb1-linked retinitis pigmentosa
EP3606544B1 (en) 2017-04-05 2025-06-04 University of Massachusetts Minigene therapy
CN108728465A (zh) 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
US20200123566A1 (en) 2017-06-13 2020-04-23 Oncosec Medical Incorporated Multigene construct for immune-modulatory protein expression and methods of use
PL3638776T3 (pl) * 2017-06-14 2026-02-23 Technische Universität Dresden Sposoby i środki do zmiany genetycznej genomów z wykorzystaniem projektowanych enzymów rekombinujących dna
CA3075168A1 (en) 2017-09-08 2019-03-14 Generation Bio Co. Modified closed-ended dna (cedna)
WO2019057774A1 (en) 2017-09-19 2019-03-28 Deutsches Krebsforschungszentrum NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS
EP3456821B2 (en) 2017-09-19 2024-01-24 Deutsches Krebsforschungszentrum Non-integrating dna vectors for the genetic modification of cells
US20200048716A1 (en) 2017-11-03 2020-02-13 Twister Biotech, Inc Using minivectors to treat ovarian cancer
AU2019240068B2 (en) 2018-03-21 2025-03-13 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
MA52709A (fr) 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
WO2020077159A1 (en) 2018-10-10 2020-04-16 The Johns Hopkins University POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY
EP3864169A4 (en) 2018-10-12 2022-07-06 Children's Hospital Medical Center MODULAR EXPRESSION SYSTEMS FOR GENE EXPRESSION AND METHODS FOR THEIR USE
WO2020081768A1 (en) 2018-10-19 2020-04-23 New England Biolabs, Inc. Improved ordered assembly of multiple dna fragments
CN109402168A (zh) 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
TWI850282B (zh) 2018-11-27 2024-08-01 香港商弘年發展有限公司 用於治療癌症之質體建構體和使用方法
CN111378677A (zh) 2018-12-27 2020-07-07 南京中科游子生物技术研究院有限公司 一种dna组装的方法及其应用
JP7332699B2 (ja) 2019-01-15 2023-08-23 ユニバーシティ オブ メリーランド，ボルチモア カウンティ 環状及び線状ｄｎａ分子を規則正しく構築する方法
US11959069B2 (en) 2019-02-28 2024-04-16 Proteonic Biotechnology Ip B.V. Self-immolative plasmid backbone
EP3956453A4 (en) 2019-04-19 2023-02-22 University of Massachusetts GENE THERAPIES FOR USHER SYNDROME (USH1B)
US12516097B2 (en) 2019-04-19 2026-01-06 University Of Massachusetts Gene therapies for Stargardt disease (ABCA4)
US20220202959A1 (en) 2019-04-19 2022-06-30 University Of Massachusetts Gene therapies for usher syndrome (ush2a)
CN110684798A (zh) 2019-09-03 2020-01-14 深圳新诺微环生物科技有限公司 肌肉靶向的微环dna基因治疗
CN110564751A (zh) 2019-09-03 2019-12-13 深圳新诺微环生物科技有限公司 微环dna疫苗设计及应用
WO2021055760A1 (en) 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032092A1 (en) * 1995-02-23 2003-02-13 Francis Blanche DNA molecules, preparation and use in gene therapy
US20130203121A1 (en) * 2010-10-05 2013-08-08 Rentschler Biotechnologie Gmbh Methods for the semi-synthetic production of high purity "minicircle" dna vectors from plasmids
US20170327797A1 (en) * 2015-01-27 2017-11-16 Hoffmann-La Roche Inc. Recombinant hbv cccdna, the method to generate thereof and the use thereof
US20190169637A1 (en) * 2015-09-22 2019-06-06 Julius-Maximilians-Universität Würzburg A method for high level and stable gene transfer in lymphocytes
US20180305701A1 (en) * 2017-03-14 2018-10-25 Baylor College Of Medicine Targeting minivectors to specific tissue using shape
CN111954528A (zh) * 2018-03-15 2020-11-17 星际治疗有限公司 合成dna运载体及使用方法

Also Published As

Publication number Publication date
EP4031168A4 (en) 2023-10-11
JP2025176040A (ja) 2025-12-03
US11602569B2 (en) 2023-03-14
US20230089543A1 (en) 2023-03-23
US11766490B2 (en) 2023-09-26
WO2021055760A1 (en) 2021-03-25
GB2700048B (en) 2026-03-04
GB202509154D0 (en) 2025-07-23
GB2700048A (en) 2025-08-13
US20210322579A1 (en) 2021-10-21
US20210322576A1 (en) 2021-10-21
JP2022549138A (ja) 2022-11-24
EP4031168A1 (en) 2022-07-27
TW202124722A (zh) 2021-07-01
MX2022003291A (es) 2022-09-09
GB2606844B (en) 2025-08-06
CA3151464A1 (en) 2021-03-25
US20210330817A1 (en) 2021-10-28
AU2020351204A1 (en) 2022-04-21
US11324839B2 (en) 2022-05-10
US20230270888A1 (en) 2023-08-31
GB2606844A (en) 2022-11-23
IL291437A (en) 2022-05-01
US20220168451A1 (en) 2022-06-02
KR20220128607A (ko) 2022-09-21
US11684680B2 (en) 2023-06-27
GB202204355D0 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
JP2025176040A (ja) 合成ｄｎａベクターおよびその使用法
CN111954528A (zh) 合成dna运载体及使用方法
JP7803917B2 (ja) 脂質ナノ粒子を用いるインビトロでのｍｒｎａの送達方法
US20180044662A1 (en) Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
KR20200079497A (ko) 제제
JP2001504325A (ja) 回帰的配列シャフリングおよび選択による遺伝子治療の最適化のための方法
US20250382631A1 (en) Protac-cid systems for use in multiplex gene regulation
CN114364440B (zh) Aav介导的rpgr x连锁视网膜变性的基因编辑治疗
JP2023507174A (ja) Ｄｍｄ変異の修正のための方法及び組成物
EP3792347A1 (en) Method for producing homozygous cells
US20250051749A1 (en) Novel promoter and use thereof
Hu et al. Co-opting regulation bypass repair as a gene-correction strategy for monogenic diseases
CN111296364B (zh) 一种基因改造的小鼠动物模型基因改造方法及其应用
CN117561331A (zh) 用于产生经基因修饰的原代细胞的方法和组合物
US20220411826A1 (en) Co-opting regulatory bypass repair of genetic diseases
HK40130757A (en) Synthetic dna vectors and method of use
EP4705442A1 (en) Myotis lucifugus transposase engineering

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240722

Address after: North Dakota, USA

Applicant after: Aldeflon LLC

Country or region after: U.S.A.

Address before: Massachusetts, USA

Applicant before: Star therapy Ltd.

Country or region before: U.S.A.

TA01 Transfer of patent application right